The PTEN/PISK/AKtpathway is a critical regulator of prostate carcinogenesis. Loss of the lipid phosphatase activity of PTEN and constitutive activation of phosphoinositide-3 kinase and Akt occur in high-grade and metastatic prostate cancers at high frequency. In the initial grant period we modeled the consequences of Akt activation in the murine prostate by developing a transgenicline (AKT1-Tg) where expressionof myristoylated, and hence activated human AKT1 is spatially restricted to the ventral prostate. These mice develop a highly penetrant prostatic intraepithelial neoplasia phenotype {Majumder, 2003 #1171}. We showed 1) that the phenotype is completely mTOR dependent {Majumder, 2004 #1170} 2) that the Hif1 D pathway is activated downstream of mTOR in this model and can acts as pharmacodynamic marker of mTOR activity;3) that phosphorylation of eiF4G is a robust tissue marker of mTOR activity in mice and in humans {Majumder, 2004 #1170} (Tabernero et. al., in prep.);4) that p27 acts as a phenotype checkpoint limiting progression to invasive cancer (Majumder et. al.,submitted), and 5) have confirmed the discovery of TMPRSS2:ERG translocation, and shown that this frequently co-occurs with PTEN deletion and that the endogenous TMPRSS2 transcript is regulated by mTOR signaling. Based on these data and other data illustrated in the preliminary data section we propose:
Specific Aim 1 : To validate pharmacodynamic signatures of mTOR activity in murine prostate models of PI3K pathway activation. To validate refined signatures of mTOR activity in clinical samples obtained in a clinical trial of RAD001 in prostate cancer patients.
Specific Aim 2 : To identifying a """"""""response"""""""" signature in the AKT1-Tg model mouse. To cross-validate the response signature in murine models of PTEN loss and/or PI3K activation. To initiated validation studies in human plasma and prostate cancer samples.
Specific Aim 3 : To determine whether PI3K/AKT/mTOR pathway activation and TMPRSS2:ERG cooperate to induce transformation of the murine prostate.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Patnaik, Akash; Swanson, Kenneth D; Csizmadia, Eva et al. (2017) Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov 7:750-765
Lee, So Jin; Kim, Min Ju; Kwon, Ick Chan et al. (2016) Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev 104:2-15
Martin, Neil E; Gerke, Travis; Sinnott, Jennifer A et al. (2015) Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res 13:1431-40
González-Billalabeitia, Enrique; Seitzer, Nina; Song, Su Jung et al. (2014) Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 4:896-904
Flavin, Richard; Pettersson, Andreas; Hendrickson, Whitney K et al. (2014) SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 20:4904-11
Selvarajah, Shamini; Pyne, Saumyadipta; Chen, Eleanor et al. (2014) High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res 20:1521-30
Ittmann, Michael; Huang, Jiaoti; Radaelli, Enrico et al. (2013) Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73:2718-36
Chen, Sen; Jiang, Xinnong; Gewinner, Christina A et al. (2013) Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal 6:ra40
Jia, Shidong; Gao, Xueliang; Lee, Sang Hyun et al. (2013) Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3:44-51
Polkinghorn, William R; Parker, Joel S; Lee, Man X et al. (2013) Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 3:1245-53

Showing the most recent 10 out of 94 publications